Press Room

Event

Webinar - Particle Engineering of Biopharmaceuticals

Start
Wednesday, December 09, 2020 - 16:00
End
Wednesday, December 09, 2020 - 16:00
Location: online
Biopharmaceuticals Spray Drying Inhalation Drug Product | Hovione

 

 

 

 

 

 

 

 

 

Wednesday, December 9th, 2020

4:00 pm GMT | 11:00 am EDT | 5:00 pm CEST

Registrations to the webinar are subject to approval

 

Watch On-Demand Webinar

 

Speakers
Diana Fernandes, MSc - Scientist, Particle Design & Formulation, R&D Drug Product Development
Paulo Lino, PhD - Scientist, Particle Design & Formulation, R&D Drug Product Development

 

 

Biopharmaceuticals represent the most promising and fastest growing field in the pharmaceutical area. These therapeutics show very high specificity and potency at relatively low concentrations and enable the treatment of otherwise untreatable diseases. Challenges in their delivery arise due to the inherent complex nature of large molecules which requires additional effort to improve bioavailability, shelf-life and patient-compliant delivery.

Freeze-drying has been the gold-standard in the isolation of large molecules in the solid form. Despite its prevalence and track record in the industry, presents several limitations that may be addressed by alternative technologies.

In this webinar we will discuss the advantages and disadvantages of the most promising alternatives to freeze drying with focus on particle engineering methods such as spray drying and spray freeze drying. Alternative methods pose many advantages in terms of costs, throughput and potential for alternate delivery routes. A series of case-studies will also be shown for each of the relevant technologies. Register Now!

 

What can you learn from this webinar?

Want to know how to spray dry your biologic? Our scientists will share their views and tell you how.

 

Watch On-Demand Webinar

Also in the Press Room

See All

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Dear Customer, As you may be aware, Portugal and Spain experienced yesterday, April 28 (at approximately 11:30) a widespread power outage. This unexpected event, beyond our control, affected the normal activities at our sites in Portugal. In response, we promptly activated our contingency protocols for this type of situation, prioritizing the safety of facilities and personnel. All ongoing processes were taken to safe hold points, and no new processes were initiated. Our backup power generators ensured continuity of critical functions throughout the duration of the outage, which lasted approximately 11 hours, until the power from the grid was restored at the site. The site began resuming operations gradually through the night making sure all systems being restarted safely and verified to be in good working conditions. We anticipate that most activities will be fully resumed during today. Should you have any specific questions regarding your product or project, we kindly encourage you to contact your Account Manager or Project Manager, who will be glad to assist you. We sincerely appreciate your understanding and continued partnership.      

News
News release, 29 April 2025

Widespread power outage in Portugal - Message to our clients

Apr 29, 2025

In a recent appearance on CNN Portugal’s Pitch – Brand & Content program, Ilda Ventura, Senior Vice President of Human Resources at Hovione, highlighted a powerful reality: 55% of our employees in Science, Technology, Engineering, and Mathematics (STEM) roles are women. At Hovione, we’re proud to foster an environment where women in science thrive - leading innovation, driving progress, and shaping the future of healthcare. But our commitment goes beyond numbers - it’s about creating the right conditions for scientific talent to grow, equally and globally. “I am proud to say that, in our company, there is no gender pay gap between men and women. We empower everyone. Our female and male scientists are all working to find more sustainable, faster, and more productive ways to achieve victories over diseases.” - Ilda Ventura Watch the full edition to learn more about our commitment to women in science at CNNPortugal.pt  (Language: Portuguese)  

Press Clipping
CNN Portugal, 15 March 2025

Ilda Ventura broadcasted on CNN Portugal

Mar 15, 2025

Also in Events

See All